PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.81%
EBIT growth of 41.81% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
41.81%
Operating income growth of 41.81% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand.
45.90%
Net income growth of 45.90% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see potential if moderate gains can keep rising.
47.62%
EPS growth of 47.62% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
47.62%
Diluted EPS growth of 47.62% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4156.92%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-4156.92%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-103.85%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-103.85%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-103.85%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
83.46%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 19.19% over a decade. Joel Greenblatt might see a standout compounder of earnings.
83.46%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 32.15%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
83.46%
3Y net income/share CAGR of 83.46% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a small advantage that can be scaled further.
-57.10%
Negative 10Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-57.10%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-57.10%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 4.05%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.34%
AR growth of 56.34% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
No Data
No Data available this quarter, please select a different quarter.
-3.01%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-2.09%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.81%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.